Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.81 |
| ▸ | LTA4H | P09960 | 6/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870502 | 0.89 | EPHX2 (1.00) | EPHX2LTA4HFAAHCNR2NPC1 | |
| SCHEMBL14161820 | 0.88 | EPHX2 (0.64) | EPHX2LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4878220 | 0.87 | EPHX2 (0.82) | EPHX2FAAHCNR2 | |
| SCHEMBL4879011 | 0.85 | EPHX2 (1.00) | EPHX2FAAHCNR2 | |
| SCHEMBL4883316 | 0.83 | EPHX2 (1.00) | EPHX2LTA4HFAAHCNR2NPC1 | |
| SCHEMBL4879161 | 0.78 | EPHX2 (0.79) | EPHX2LTA4HFAAHCNR2 | |
| SCHEMBL4882753 | 0.78 | EPHX2 (1.00) | EPHX2LTA4HFAAHCNR2NPC1 | |
| SCHEMBL14086737 | 0.78 | EPHX2 (1.00) | EPHX2LTA4HFAAHCNR2NPC1 | |
| SCHEMBL14161825 | 0.77 | EPHX2 (0.66) | EPHX2LTA4HFAAHCNR2 | |
| SCHEMBL4877187 | 0.76 | EPHX2 (0.68) | EPHX2LTA4HFAAHCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885LTA4H 5/4885FAAH 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.